Home
Pharmaxis

Pharmaxis Market Share Analysis for April 2026

welcome to the pharmaxis staging website.

Health > Biotechnology and Pharmaceuticals

Domainpharmaxis.com.au

Year Founded1998

Employees51 - 200

Annual Revenue$15M - $25M

Pharmaxis

Pharmaxis (including company regionals)

pharmaxis.com.au

See more website traffic and engagement information

Pharmaxis Revenue up to April 2026 is 15M - 25M

revenue generated by Pharmaxis top domains

Pharmaxis top domains revenue over 3 years

Revenue for Pharmaxis top domains

pharmaxis.com.au15M - 25M

See more with Sales Intelligence

Total visits to Pharmaxis's top domains

Understand Pharmaxis market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Pharmaxis's top domains

Analyze Pharmaxis engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Pharmaxis's top domains

See how Pharmaxis keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Pharmaxis top competitors by domain

Top similar sites in April 2026, ranked by their affinity

kamada.comCompany NameKamadaEmployees201 - 500HQIsrael, rehovotAnnual revenue$100M - $200MTotal visits6.1KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Pharmaxis

These are the website technologies, by industry, used by Pharmaxis top domains

Audio Video Media (2)

YouTube

Mobile (2)

Meta Viewport

Payment & Currencies (2)

Euro

Advertising (1)

PubMatic

More Technologies

2

See all

News & Signals from Pharmaxis

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPharmaxis sold assets to Aptar Pharma on Aug 1st '22.In August 2022, AptarGroup Inc. acquired worldwide rights to the proprietary Orbital dry powder inhaler (DPI) from Pharmaxis Inc. for an undisclosed amount.

NewsPharmaxis launches Phase IIa monotherapy study.Pharmaxis is conducting a Phase IIa monotherapy study in up to 24 patients with myelofibrosis with its drug candidate PXS-5505.

NewsPharmaxis hires Hashan De Silva as non-executive director.Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) has strengthened its board through the appointment of experienced life sciences investment professional Hashan De Silva as a non-executive director.